{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T00:55:37Z","timestamp":1789606537606,"version":"build-2803163510"},"reference-count":75,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,1,6]],"date-time":"2020-01-06T00:00:00Z","timestamp":1578268800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,1,6]],"date-time":"2020-01-06T00:00:00Z","timestamp":1578268800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"CIHR Drug Safety and Effectiveness Network (DSEN) grant","award":["grant number: 126639"],"award-info":[{"award-number":["grant number: 126639"]}]},{"name":"Canadian Institutes for Health Research Sponsorship Grant","award":["CIHR (sponsor award number 156306)"],"award-info":[{"award-number":["CIHR (sponsor award number 156306)"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Given the complex nature of opioid addiction treatment and the rising number of available opioid substitution and antagonist therapies (OSAT), there is no \u2018gold standard\u2019 measure of treatment effectiveness, and each successive trial measures a different set of outcomes which reflect success in arbitrary or opportune terms. We sought to describe the variation in current outcomes employed across clinical trials for opioid addiction, as well as determine whether a discrepancy exists between the treatment targets that patients consider important and how treatment effectiveness is measured in the literature.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We searched nine commonly used databases (e.g., EMBASE, MEDLINE) from inception to August 1, 2015. Outcomes used across trials were extracted and categorized according to previously established domains. To evaluate patient-reported goals of treatment, semi-structured interviews were conducted with 18 adults undergoing methadone treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      We identified 60 trials eligible for inclusion. Once outcomes were categorized into eight broad domains (e.g., abstinence\/substance abuse), we identified 21 specific outcomes with furthermore 53 subdomains and 118 measurements. Continued opioid use and treatment retention were the most commonly reported measures (46%,\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200928). The majority of patients agreed that abstinence from opioids was a primary goal in their treatment, although they also stressed goals under-reported in clinical trials.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>There is inconsistency in the measures used to evaluate the effectiveness of OSATs. Individual and population level decision making is being guided by a standard of effect considered useful to researchers yet in direct conflict with what patients deem important.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>PROSPERO, CRD42013006507.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13063-019-3995-y","type":"journal-article","created":{"date-parts":[[2020,1,6]],"date-time":"2020-01-06T09:02:46Z","timestamp":1578301366000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["A call for consensus in defining efficacy in clinical trials for opioid addiction: combined results from a systematic review and qualitative study in patients receiving pharmacological assisted therapy for opioid use disorder"],"prefix":"10.1186","volume":"21","author":[{"given":"Brittany B.","family":"Dennis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nitika","family":"Sanger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Bawor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leen","family":"Naji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn","family":"Plater","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Worster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Woo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anuja","family":"Bhalerao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natasha","family":"Baptist-Mohseni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alannah","family":"Hillmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle","family":"Rice","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim","family":"Corace","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Hutton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Tugwell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lehana","family":"Thabane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5974-9361","authenticated-orcid":false,"given":"Zainab","family":"Samaan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,1,6]]},"reference":[{"key":"3995_CR1","doi-asserted-by":"publisher","first-page":"137","DOI":"10.4103\/2229-3485.86879","volume":"2","author":"PR Deshpande","year":"2011","unstructured":"Deshpande PR, Rajan S, Sudeepthi BL, Abdul Nazir CP. Patient-reported outcomes: a new era in clinical research. Perspect Clin Res. 2011;2:137\u201344.","journal-title":"Perspect Clin Res"},{"key":"3995_CR2","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.2337\/dc06-0077","volume":"29","author":"VM Montori","year":"2006","unstructured":"Montori VM, Wang YG, Alonso-Coello P, Bhagra S. Systematic evaluation of the quality of randomized controlled trials in diabetes. Diabetes Care. 2006;29:1833\u20138.","journal-title":"Diabetes Care"},{"key":"3995_CR3","doi-asserted-by":"publisher","unstructured":"American Psychiatric Association. Diagnostic and statistical manual of mental disorders (5th ed.). 2013. https:\/\/doi.org\/10.1176\/appi.books.9780890425596.","DOI":"10.1176\/appi.books.9780890425596"},{"key":"3995_CR4","doi-asserted-by":"publisher","unstructured":"Mattick Richard P, Breen C, Kimber J, Davoli M. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database Syst Rev. 2009. https:\/\/doi.org\/10.1002\/14651858.CD002209.pub2.","DOI":"10.1002\/14651858.CD002209.pub2"},{"key":"3995_CR5","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1111\/j.1360-0443.2011.03676.x","volume":"107","author":"D Hedrich","year":"2012","unstructured":"Hedrich D, et al. The effectiveness of opioid maintenance treatment in prison settings: a systematic review. Addiction. 2012;107:501\u201317.","journal-title":"Addiction"},{"key":"3995_CR6","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/BF03256276","volume":"12","author":"Y Li","year":"2008","unstructured":"Li Y, Kantelip J-P, Gerritsen-van Schieveen P, Davani S. Interindividual variability of methadone response. Mol Diagn Ther. 2008;12:109\u201324.","journal-title":"Mol Diagn Ther"},{"key":"3995_CR7","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/2046-4053-3-105","volume":"3","author":"BB Dennis","year":"2014","unstructured":"Dennis BB, Naji L, Bawor M, Bonner A, Varenbut M, Daiter J, Plater C, Pare G, Marsh DC, Worster A, Desai D. The effectiveness of opioid substitution treatments for patients with opioid dependence: a systematic review and multiple treatment comparison protocol. Syst Rev. 2014;3:105.","journal-title":"Syst Rev"},{"key":"3995_CR8","doi-asserted-by":"publisher","first-page":"g7647","DOI":"10.1136\/bmj.g7647","volume":"349","author":"L Shamseer","year":"2015","unstructured":"Shamseer L, et al. Preferred reporting items for systematic review and meta-analysis protocols (prisma-p) 2015: Elaboration and explanation. BMJ. 2015;349:g7647.","journal-title":"BMJ"},{"key":"3995_CR9","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/0740-5472(92)90062-S","volume":"9","author":"AT McLellan","year":"1992","unstructured":"McLellan AT, et al. The fifth edition of the Addiction Severity Index. J Subst Abus Treat. 1992;9:199\u2013213.","journal-title":"J Subst Abus Treat"},{"issue":"12","key":"3995_CR10","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.1046\/j.1360-0443.1998.9312185711.x","volume":"93","author":"John Marsden","year":"1998","unstructured":"Marsden J, Gossop G, Stewart D, Best D, Farrell M, Lehmann P, Edwards C, Strang J. The Maudsley Addiction Profile (MAP): A brief instrument for assessing treatment outcome. Addiction. 1998;93(12):1857\u201367.","journal-title":"Addiction"},{"key":"3995_CR11","doi-asserted-by":"publisher","unstructured":"Woo J, et al. \u201cDont judge a book by its cover\u201d: a qualitative study of methadone patients\u2019 experiences of stigma. Subst Abus Res Treat. 2017. https:\/\/doi.org\/10.1177\/1178221816685087.","DOI":"10.1177\/1178221816685087"},{"key":"3995_CR12","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1136\/bmj.39335.541782.AD","volume":"335","author":"E von Elm","year":"2007","unstructured":"von Elm E, et al. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. BMJ. 2007;335:806\u20138.","journal-title":"BMJ"},{"key":"3995_CR13","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/BF02915283","volume":"172","author":"J Ahmadi","year":"2003","unstructured":"Ahmadi J, Ahmadi K. Controlled trial of maintenance treatment of intravenous buprenorphine dependence. Ir J Med Sci. 2003;172:171\u20133.","journal-title":"Ir J Med Sci"},{"key":"3995_CR14","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1136\/bmj.327.7410.310","volume":"327","author":"W van den Brink","year":"2003","unstructured":"van den Brink W, et al. Medical prescription of heroin to treatment resistant heroin addicts: two randomised controlled trials. BMJ. 2003;327:310.","journal-title":"BMJ"},{"key":"3995_CR15","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1001\/archpsyc.1996.01830050035005","volume":"53","author":"W Ling","year":"1996","unstructured":"Ling W, Wesson DR, Charuvastra C, Klett CJ. A controlled trial comparing buprenorphine and methadone maintenance in opioid dependence. Arch Gen Psychiatry. 1996;53:401\u20137.","journal-title":"Arch Gen Psychiatry"},{"key":"3995_CR16","doi-asserted-by":"publisher","first-page":"2192","DOI":"10.1016\/S0140-6736(08)60954-X","volume":"371","author":"RS Schottenfeld","year":"2008","unstructured":"Schottenfeld RS, Chawarski MC, Mazlan M. Maintenance treatment with buprenorphine and naltrexone for heroin dependence in Malaysia: a randomised, double-blind, placebo-controlled trial. Lancet. 2008;371:2192\u2013200.","journal-title":"Lancet"},{"key":"3995_CR17","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/0376-8716(95)01186-2","volume":"40","author":"RE Johnson","year":"1995","unstructured":"Johnson RE, et al. A placebo controlled clinical trial of buprenorphine as a treatment for opioid dependence. Drug Alcohol Depend. 1995;40:17\u201325.","journal-title":"Drug Alcohol Depend"},{"key":"3995_CR18","first-page":"1","volume":"7","author":"J Ahmadi","year":"2004","unstructured":"Ahmadi J, Moosavinasab M, Babaee M, Firoozabadi A, Mohagheghzadeh M, et al. F. H. Treatment of heroin dependence. Ger J Psychiatry. 2004;7:1\u20135.","journal-title":"Ger J Psychiatry"},{"key":"3995_CR19","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/S0376-8716(01)00202-2","volume":"66","author":"J Ahmadi","year":"2002","unstructured":"Ahmadi J. A controlled trial of buprenorphine treatment for opium dependence: the first experience from Iran. Drug Alcohol Depend. 2002;66:111\u20134.","journal-title":"Drug Alcohol Depend"},{"key":"3995_CR20","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.2105\/AJPH.81.9.1185","volume":"81","author":"SR Yancovitz","year":"1991","unstructured":"Yancovitz SR, et al. A randomized trial of an interim methadone maintenance clinic. Am J Public Heal. 1991;81:1185\u201391.","journal-title":"Am J Public Heal"},{"key":"3995_CR21","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1001\/jama.283.10.1303","volume":"283","author":"KL Sees","year":"2000","unstructured":"Sees KL, et al. Methadone maintenance vs 180-day psychosocially enriched detoxification for treatment of opioid dependence: a randomized controlled trial. JAMA. 2000;283:1303\u201310.","journal-title":"JAMA"},{"key":"3995_CR22","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1176\/ajp.151.7.1025","volume":"151","author":"EC Strain","year":"1994","unstructured":"Strain EC, Stitzer ML, Liebson IA, Bigelow GE. Comparison of buprenorphine and methadone in the treatment of opioid dependence. Am J Psychiatry. 1994;151:1025\u201330.","journal-title":"Am J Psychiatry"},{"key":"3995_CR23","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1017\/S146114570700836X","volume":"11","author":"M Soyka","year":"2008","unstructured":"Soyka M, Zingg C, Koller G, Kuefner H. Retention rate and substance use in methadone and buprenorphine maintenance therapy and predictors of outcome: results from a randomized study. Int J Neuropsychopharmacol. 2008;11:641\u201353.","journal-title":"Int J Neuropsychopharmacol"},{"key":"3995_CR24","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.jsat.2006.04.007","volume":"31","author":"JC March","year":"2006","unstructured":"March JC, Oviedo-Joekes E, Perea-Milla E, Carrasco F. Controlled trial of prescribed heroin in the treatment of opioid addiction. J Subst Abus Treat. 2006;31:203\u201311.","journal-title":"J Subst Abus Treat"},{"key":"3995_CR25","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1001\/archpsyc.63.2.210","volume":"63","author":"SD Comer","year":"2006","unstructured":"Comer SD, et al. Injectable, sustained-release naltrexone for the treatment of opioid dependence: a randomized, placebo-controlled trial. Arch Gen Psychiatry. 2006;63:210\u20138.","journal-title":"Arch Gen Psychiatry"},{"key":"3995_CR26","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1111\/j.1360-0443.2005.001128.x","volume":"100","author":"H Eder","year":"2005","unstructured":"Eder H, et al. Comparative study of the effectiveness of slow-release morphine and methadone for opioid maintenance therapy. Addiction (Abingdon, England). 2005;100:1101\u20139.","journal-title":"Addiction (Abingdon, England)"},{"key":"3995_CR27","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1001\/jama.1997.03540480045037","volume":"277","author":"T Eissenberg","year":"1997","unstructured":"Eissenberg T, et al. Dose-related efficacy of levomethadyl acetate for treatment of opioid dependence. A randomized clinical trial. JAMA. 1997;277:1945\u201351.","journal-title":"JAMA"},{"key":"3995_CR28","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1001\/jama.1972.03210040013004","volume":"222","author":"JH Jaffe","year":"1972","unstructured":"Jaffe JH, et al. Methadyl acetate vs methadone. A double-blind study in heroin users. JAMA. 1972;222:437\u201342.","journal-title":"JAMA"},{"key":"3995_CR29","first-page":"5","volume":"10","author":"JB Kamien","year":"2008","unstructured":"Kamien JB, Branstetter SA, Amass L. Buprenorphine-naloxone versus methadone maintenance therapy: A randomised double-blind trial with opioid-dependent patients. Heroin Addict Relat Clin Probl. 2008;10:5\u201318.","journal-title":"Heroin Addict Relat Clin Probl"},{"key":"3995_CR30","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.jsat.2006.05.014","volume":"31","author":"VL King","year":"2006","unstructured":"King VL, et al. A 12-month controlled trial of methadone medical maintenance integrated into an adaptive treatment model. J Subst Abus Treat. 2006;31:385\u201393.","journal-title":"J Subst Abus Treat"},{"key":"3995_CR31","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1056\/NEJMoa0810635","volume":"361","author":"E Oviedo-Joekes","year":"2009","unstructured":"Oviedo-Joekes E, et al. Diacetylmorphine versus methadone for the treatment of opioid addiction. N Engl J Med. 2009;361:777\u201386.","journal-title":"N Engl J Med"},{"key":"3995_CR32","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1111\/j.1465-3362.2009.00100.x","volume":"29","author":"E Oviedo-Joekes","year":"2010","unstructured":"Oviedo-Joekes E, March JC, Romero M, Perea-Milla E. The Andalusian trial on heroin-assisted treatment: a 2 year follow-up. Drug Alcohol Rev. 2010;29:75\u201380.","journal-title":"Drug Alcohol Rev"},{"key":"3995_CR33","doi-asserted-by":"publisher","first-page":"605","DOI":"10.15288\/jsad.2013.74.605","volume":"74","author":"JS Potter","year":"2013","unstructured":"Potter JS, et al. Buprenorphine\/naloxone and methadone maintenance treatment outcomes for opioid analgesic, heroin, and combined users: findings from starting treatment with agonist replacement therapies (START). J Stud Alcohol Drugs. 2013;74:605\u201313.","journal-title":"J Stud Alcohol Drugs"},{"key":"3995_CR34","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.1111\/j.1360-0443.2006.01603.x","volume":"101","author":"JR Robertson","year":"2006","unstructured":"Robertson JR, et al. Addressing the efficacy of dihydrocodeine versus methadone as an alternative maintenance treatment for opiate dependence: A randomized controlled trial. Addiction. 2006;101:1752\u20139.","journal-title":"Addiction"},{"key":"3995_CR35","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.drugalcdep.2012.08.002","volume":"128","author":"AJ Saxon","year":"2013","unstructured":"Saxon AJ, et al. Buprenorphine\/Naloxone and methadone effects on laboratory indices of liver health: a randomized trial. Drug Alcohol Depend. 2013;128:71\u20136.","journal-title":"Drug Alcohol Depend"},{"key":"3995_CR36","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1111\/j.1360-0443.2007.01935.x","volume":"102","author":"MD Anglin","year":"2007","unstructured":"Anglin MD, Conner BT, Annon J, Longshore D. Levo-alpha-acetylmethadol (LAAM) versus methadone maintenance: 1-year treatment retention, outcomes and status. Addiction. 2007;102:1432\u201342.","journal-title":"Addiction"},{"key":"3995_CR37","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.jsat.2011.01.008","volume":"41","author":"RP Schwartz","year":"2011","unstructured":"Schwartz RP, Kelly SM, O\u2019Grady KE, Gandhi D, Jaffe JH. Interim methadone treatment compared to standard methadone treatment: 4-month findings. J Subst Abus Treat. 2011;41:21\u20139.","journal-title":"J Subst Abus Treat"},{"key":"3995_CR38","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1001\/archpsyc.63.1.102","volume":"63","author":"RP Schwartz","year":"2006","unstructured":"Schwartz RP, et al. A randomized controlled trial of interim methadone maintenance. Arch Gen Psychiatry. 2006;63:102\u20139.","journal-title":"Arch Gen Psychiatry"},{"key":"3995_CR39","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1097\/00004714-199602000-00010","volume":"16","author":"EC Strain","year":"1996","unstructured":"Strain EC, Stitzer ML, Liebson IA, Bigelow GE. Buprenorphine versus methadone in the treatment of opioid dependence: self-reports, urinalysis, and addiction severity index. J Clin Psychopharmacol. 1996;16:58\u201367.","journal-title":"J Clin Psychopharmacol"},{"key":"3995_CR40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1055\/s-0028-1083818","volume":"42","author":"J Wolstein","year":"2009","unstructured":"Wolstein J, et al. A randomized, open-label trial comparing methadone and Levo-Alpha-Acetylmethadol (LAAM) in maintenance treatment of opioid addiction. Pharmacopsychiatry. 2009;42:1\u20138.","journal-title":"Pharmacopsychiatry"},{"key":"3995_CR41","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1001\/archpsyc.1976.01770060043007","volume":"33","author":"W Ling","year":"1976","unstructured":"Ling W, Charuvastra VC, Kaim SC, Klett CJ. Methadyl acetate and methadone as maintenance treatments for heroin addicts: a Veterans Administration cooperative study. Arch Gen Psychiatry. 1976;33:709\u201320.","journal-title":"Arch Gen Psychiatry"},{"key":"3995_CR42","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/S0376-8716(02)00007-8","volume":"66","author":"JM White","year":"2002","unstructured":"White JM, et al. Relationship between LAAM-methadone preference and treatment outcomes. Drug Alcohol Depend. 2002;66:295\u2013301.","journal-title":"Drug Alcohol Depend"},{"key":"3995_CR43","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1097\/00005053-199306000-00004","volume":"181","author":"TR Kosten","year":"1993","unstructured":"Kosten TR, Schottenfeld R, Ziedonis D, Falcioni J. Buprenorphine versus methadone maintenance for opioid dependence. J Nerv Ment Dis. 1993;181:358\u201364.","journal-title":"J Nerv Ment Dis"},{"key":"3995_CR44","doi-asserted-by":"publisher","first-page":"2469","DOI":"10.1001\/archinte.167.22.2469","volume":"167","author":"EF Wedam","year":"2007","unstructured":"Wedam EF, Bigelow GE, Johnson RE, Nuzzo PA, Haigney MCP. QT-interval effects of methadone, levomethadyl, and buprenorphine in a randomized trial. Arch Intern Med. 2007;167:2469\u201375.","journal-title":"Arch Intern Med"},{"key":"3995_CR45","doi-asserted-by":"publisher","first-page":"2003","DOI":"10.1001\/jama.2008.574","volume":"300","author":"GE Woody","year":"2008","unstructured":"Woody GE, et al. Extended vs short-term buprenorphine-naloxone for treatment of opioid-addicted youth: a randomized trial. JAMA. 2008;300:2003\u201311.","journal-title":"JAMA"},{"key":"3995_CR46","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1016\/S0140-6736(03)12600-1","volume":"361","author":"J Kakko","year":"2003","unstructured":"Kakko J, Svanborg KD, Kreek MJ, Heilig M. 1-year retention and social function after buprenorphine-assisted relapse prevention treatment for heroin dependence in Sweden: a randomised, placebo-controlled trial. Lancet. 2003;361:662\u20138.","journal-title":"Lancet"},{"key":"3995_CR47","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1046\/j.1360-0443.1999.94913376.x","volume":"94","author":"G Fischer","year":"1999","unstructured":"Fischer G, et al. Buprenorphine versus methadone maintenance for the treatment of opioid dependence. Addiction (Abingdon, England). 1999;94:1337\u201347.","journal-title":"Addiction (Abingdon, England)"},{"key":"3995_CR48","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1046\/j.1360-0443.2002.00090.x","volume":"97","author":"AL Krook","year":"2002","unstructured":"Krook AL, et al. A placebo-controlled study of high dose buprenorphine in opiate dependents waiting for medication-assisted rehabilitation in Oslo, Norway. Addiction. 2002;97:533\u201342.","journal-title":"Addiction"},{"key":"3995_CR49","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1046\/j.1360-0443.1998.9344753.x","volume":"93","author":"W Ling","year":"1998","unstructured":"Ling W, et al. Buprenorphine maintenance treatment of opiate dependence: a multicenter, randomized clinical trial. Addiction. 1998;93:475\u201386.","journal-title":"Addiction"},{"issue":"Suppl 1","key":"3995_CR50","doi-asserted-by":"publisher","first-page":"S29","DOI":"10.1080\/10550490490440799","volume":"13","author":"N Lintzeris","year":"2004","unstructured":"Lintzeris N, et al. Implementing buprenorphine treatment in community settings in Australia: experiences from the Buprenorphine Implementation Trial. Am J Addict. 2004;13(Suppl 1):S29\u201341.","journal-title":"Am J Addict"},{"key":"3995_CR51","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1046\/j.1360-0443.2003.00335.x","volume":"98","author":"RP Mattick","year":"2003","unstructured":"Mattick RP, et al. Buprenorphine versus methadone maintenance therapy: a randomized double-blind trial with 405 opioid-dependent patients. Addiction. 2003;98:441\u201352.","journal-title":"Addiction"},{"key":"3995_CR52","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1007\/s00213-005-2239-x","volume":"179","author":"S Neri","year":"2005","unstructured":"Neri S, et al. Randomized clinical trial to compare the effects of methadone and buprenorphine on the immune system in drug abusers. Psychopharmacology. 2005;179:700\u20134.","journal-title":"Psychopharmacology"},{"key":"3995_CR53","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1016\/0006-3223(94)91240-8","volume":"35","author":"EN Shufman","year":"1994","unstructured":"Shufman EN, et al. The efficacy of naltrexone in preventing reabuse of heroin after detoxification. Biol Psychiatry. 1994;35:935\u201345.","journal-title":"Biol Psychiatry"},{"key":"3995_CR54","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/S0376-8716(00)80006-X","volume":"60","author":"PP Pani","year":"2000","unstructured":"Pani PP, Maremmani I, Pirastu R, Tagliamonte A, Gessa GL. Buprenorphine: a controlled clinical trial in the treatment of opioid dependence. Drug Alcohol Depend. 2000;60:39\u201350.","journal-title":"Drug Alcohol Depend"},{"key":"3995_CR55","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1097\/00005053-199801000-00006","volume":"186","author":"RS Schottenfeld","year":"1998","unstructured":"Schottenfeld RS, Pakes JR, Kosten TR. Prognostic factors in Buprenorphine- versus methadone-maintained patients. J Nerv Ment Dis. 1998;186:35\u201343.","journal-title":"J Nerv Ment Dis"},{"key":"3995_CR56","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1001\/archpsyc.57.4.395","volume":"57","author":"KL Preston","year":"2000","unstructured":"Preston KL, Umbricht A, Epstein DH. Methadone dose increase and abstinence reinforcement for treatment of continued heroin use during methadone maintenance. Arch Gen Psychiatry. 2000;57:395\u2013404.","journal-title":"Arch Gen Psychiatry"},{"key":"3995_CR57","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1176\/appi.ajp.162.2.340","volume":"162","author":"RS Schottenfeld","year":"2005","unstructured":"Schottenfeld RS, et al. Methadone versus buprenorphine with contingency management or performance feedback for cocaine and opioid dependence. Am J Psychiatry. 2005;162:340\u20139.","journal-title":"Am J Psychiatry"},{"key":"3995_CR58","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1056\/NEJMoa022164","volume":"349","author":"PJ Fudala","year":"2003","unstructured":"Fudala PJ, et al. Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone. N Engl J Med. 2003;349:949\u201358.","journal-title":"N Engl J Med"},{"key":"3995_CR59","doi-asserted-by":"publisher","first-page":"23","DOI":"10.7326\/0003-4819-119-1-199307010-00004","volume":"119","author":"EC Strain","year":"1993","unstructured":"Strain EC, Stitzer ML, Liebson IA, Bigelow GE. Dose-response effects of methadone in the treatment of opioid dependence. Ann Intern Med. 1993;119:23\u20137.","journal-title":"Ann Intern Med"},{"key":"3995_CR60","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1001\/archpsyc.1980.01780210035003","volume":"37","author":"RL Hartnoll","year":"1980","unstructured":"Hartnoll RL, et al. Evaluation of heroin maintenance in controlled trial. Arch Gen Psychiatry. 1980;37:877\u201384.","journal-title":"Arch Gen Psychiatry"},{"key":"3995_CR61","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.1016\/S0140-6736(10)60349-2","volume":"375","author":"J Strang","year":"2010","unstructured":"Strang J, et al. Supervised injectable heroin or injectable methadone versus optimised oral methadone as treatment for chronic heroin addicts in England after persistent failure in orthodox treatment (RIOTT): a randomised trial. Lancet. 2010;375:1885\u201395.","journal-title":"Lancet"},{"key":"3995_CR62","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1001\/jama.1972.03200060039005","volume":"220","author":"A Zaks","year":"1972","unstructured":"Zaks A, Fink M, Freedman AM. Levomethadyl in maintenance treatment of opiate dependence. JAMA. 1972;220:811\u20133.","journal-title":"JAMA"},{"key":"3995_CR63","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1001\/jama.281.11.1000","volume":"281","author":"EC Strain","year":"1999","unstructured":"Strain EC, Bigelow GE, Liebson IA, Stitzer ML. Moderate- vs high-dose methadone in the treatment of opioid dependence: a randomized trial. JAMA. 1999;281:1000\u20135.","journal-title":"JAMA"},{"key":"3995_CR64","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/S0376-8716(00)00163-0","volume":"62","author":"S Petitjean","year":"2001","unstructured":"Petitjean S, et al. Double-blind randomized trial of buprenorphine and methadone in opiate dependence. Drug Alcohol Depend. 2001;62:97\u2013104.","journal-title":"Drug Alcohol Depend"},{"key":"3995_CR65","first-page":"2","volume":"11","author":"S Guo","year":"2001","unstructured":"Guo S. Efficacy of naltrexone hydrochloride for preventing relapse among opiate dependent patients after detoxification. Hong Kong J Psychiatry. 2001;11:2\u20138.","journal-title":"Hong Kong J Psychiatry"},{"key":"3995_CR66","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.jsat.2004.02.002","volume":"26","author":"EM Krupitsky","year":"2004","unstructured":"Krupitsky EM, et al. Naltrexone for heroin dependence treatment in St. Petersburg, Russia. J Subst Abus Treat. 2004;26:285\u201394.","journal-title":"J Subst Abus Treat"},{"key":"3995_CR67","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1111\/j.1360-0443.1991.tb01859.x","volume":"86","author":"L San","year":"1991","unstructured":"San L, Pomarol G, Peri JM, Olle JM, Cami J. Follow-up after a six-month maintenance period on naltrexone versus placebo in heroin addicts. Br J Addict. 1991;86:983\u201390.","journal-title":"Br J Addict"},{"key":"3995_CR68","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/j.jsat.2006.05.005","volume":"31","author":"EM Krupitsky","year":"2006","unstructured":"Krupitsky EM, et al. Naltrexone with or without fluoxetine for preventing relapse to heroin addiction in St. Petersburg, Russia. J Subst Abus Treat. 2006;31:319\u201328.","journal-title":"J Subst Abus Treat"},{"key":"3995_CR69","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1100\/tsw.2005.52","volume":"5","author":"SM Giacomuzzi","year":"2005","unstructured":"Giacomuzzi SM, Ertl M, Kemmler G, Riemer Y, Vigl A. Sublingual buprenorphine and methadone maintenance treatment: a three-year follow-up of quality of life assessment. Scientific World J. 2005;5:452\u201368.","journal-title":"Scientific World J"},{"key":"3995_CR70","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1192\/bjp.bp.106.026112","volume":"191","author":"C Haasen","year":"2007","unstructured":"Haasen C, et al. Heroin-assisted treatment for opioid dependence: randomised controlled trial. Br J Psychiatry. 2007;191:55\u201362.","journal-title":"Br J Psychiatry"},{"key":"3995_CR71","doi-asserted-by":"publisher","first-page":"2750","DOI":"10.1001\/jama.1992.03480200058024","volume":"267","author":"RE Johnson","year":"1992","unstructured":"Johnson RE, Jaffe JH, Fudala PJ. A controlled trial of buprenorphine treatment for opioid dependence. JAMA. 1992;267:2750\u20135.","journal-title":"JAMA"},{"key":"3995_CR72","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1001\/archgenpsychiatry.2012.1a","volume":"69","author":"E Krupitsky","year":"2012","unstructured":"Krupitsky E, et al. Randomized trial of long-acting sustained-release naltrexone implant vs oral naltrexone or placebo for preventing relapse to opioid dependence. Arch Gen Psychiatry. 2012;69:973\u201381.","journal-title":"Arch Gen Psychiatry"},{"key":"3995_CR73","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1745-6215-16-1","volume":"16","author":"BB Dennis","year":"2015","unstructured":"Dennis BB, et al. Opioid substitution and antagonist therapy trials exclude the common addiction patient: a systematic review and analysis of eligibility criteria. Trials. 2015;16:1.","journal-title":"Trials"},{"key":"3995_CR74","doi-asserted-by":"publisher","first-page":"E247","DOI":"10.1503\/cmaj.170958","volume":"190","author":"J Bruneau","year":"2018","unstructured":"Bruneau J, et al. Management of opioid use disorders: a national clinical practice guideline. Can Med Assoc J. 2018;190:E247\u201357.","journal-title":"Can Med Assoc J"},{"key":"3995_CR75","unstructured":"Methadone maintenance treatment program standards and clinical guidelines. The College of Physicians and Surgeons of Ontario; 2011."}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-019-3995-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13063-019-3995-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-019-3995-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,4]],"date-time":"2021-01-04T19:39:38Z","timestamp":1609789178000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-019-3995-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,6]]},"references-count":75,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["3995"],"URL":"https:\/\/doi.org\/10.1186\/s13063-019-3995-y","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.2.382\/v1","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.2.382\/v2","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.2.382\/v3","asserted-by":"object"}]},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,6]]},"assertion":[{"value":"9 February 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 December 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 January 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Participants were recruited as part of the Genetics of Opioid Addiciton (GENOA) research collaborative between McMaster University and the Population Genomics Program. GENOA is a prospective cohort investigation approved by the Hamilton Integrated Research Ethics Board. Amendments to the GENOA study protocol to include new questions as part of our interview tool to allow for qualitative interviews exploring patient important outcomes was approved (HIREB #0168).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"This study does not include any individual person\u2019s data requiring consent for publication.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"30"}}